Adicet Bio, Inc. Common Stock H.C. Wainwright 28th Annual Global Investment Conference

Robert, thank you for inviting us.

Sure, absolutely. Adicet is considered to be the leader in developing a specific type of CAR T-cell therapy, gamma delta CAR T-cell therapy. It is an off-the-shelf platform that has been so far associated in a quite consistent way across all of our studies with a safety profile that seems to be more favorable than alpha beta T cells. Our lead program is in autoimmune diseases, and we expect to provide a very significant data clinical update this month. Our second program is in prostate cancer and is about to get into the clinic in the fourth quarter. We also have a pipeline of in vivo CAR Ts, and the first program we expect to put in the clinic in the second half of next year.

Expect a lot of milestones in the next 18 months, with the more immediate one is the clinical data that we expect to have in SLE and lupus nephritis.

Sure, absolutely. I'll use a slide there in a second. The key difference between alpha beta T cells, and there's autologous alpha beta T cells, and there's allogeneic alpha beta T cells, is that these cells, once dosed to patients, are associated with certain safety issues such as CRS and ICANS, and now there's an emerging safety issue called ICHS, which is essentially HLH. In our case, our cells can be provided off the shelf, have shown so far very favorable safety profile, and efficacy has been comparable to autologous CAR T in the field of autoimmune diseases. Let me walk you through one slide. Before I go there, I'll just say the following. The data set that we expect to share this month will be the largest data set by a cell therapy company or bispecific company in the field of LN and SLE globally.

The only two companies that have enrolled comparable number of patients and shared data are two small companies. One of them is Novartis, and one of them is BMS. Both of them are on clinical hold because of safety issues associated with Yeah alpha beta T cells.

We actually benefited in our enrollment from sites in the same cities that enroll to these studies. Let me walk you through an example why this is the case, and I will use a slide for this. If you are an investigator and there is a patient that comes to you, they tried a couple of different products that are approved for SLE or LN. You really do not feel well. You come to the investigator, and as an investigator, you think, "You know what? You are actually a great candidate for a cell therapy." If you want to go to an autologous cell therapy, this is what you need to tell the patient. "Well, I know you feel really, really not good because the therapies have not been working for you, and your SLE or LN is progressing towards a flare.

I need to take you off your drugs now for a couple of weeks because I need to get your T cells to a point that they have good fitness, so we can do leukapheresis. For the next few weeks, you are going to stop taking your drug. Then I am going to call this other department, and I am going to try to get a chair so we can have a leukapheresis, and we will extract the cells from you. Then I will send it to manufacturing. I will send it to a company that has a quite short manufacturing process, maybe 3 days, but it takes them quite a while to release the cells. So after I send it, at some point, I will get a call, and then I will tell you that you need to" This is literally the case. My mother got CAR T.

I will give you a call, and I will let you know when you need to come for the conditioning. Then we will give you the conditioning. Now, you should know that these alpha beta T cells are associated with ICANS and ICHS. You actually need to sign this form that you know" No, this is true. "That you know that alpha beta T cells have been associated with ICHS, and that can lead to mortality. If you sign it, then we will give it to you. Hopefully, you are not going to get it, and you are not going to get ICANS, and we will keep you in the hospital for at least a week, maybe 2 weeks, to monitor your safety.

But overall, they seem to work pretty well." We actually had cases that these investigators did not want to go through this, and in the same city, we had a site of our program, and they just sent the patients to us. This is one of the reasons you see such great enrollment. In our case, if you see a patient and they seem to benefit from cell therapy, you can tell them, "Hey, why do not we start the conditioning tomorrow, and in 5 days, you can get a drug." This type of gamma delta on T cells do not have any of these ICHS issues. No ICANS, very low-grade CRS, well-tolerated, and so far, they seem to work like autologous CAR Ts. It is pretty simple. We have shared our safety profile with the FDA, and they agreed that we can go to outpatient settings in the field of LN and SLE.

The safety here has been a big advantage.